Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
 
00.250.50.7511.251.51.752+Meizlish (PSM)48%0.52 [0.34-0.81]death319 (n)319 (n)Improvement, RR [CI]TreatmentControlLiu (PSM)75%0.25 [0.07-0.87]death2/2811/204Mura20%0.80 [0.66-0.96]death527 (n)527 (n)Chow47%0.53 [0.31-0.90]death26/9873/314Sahai (PSM)13%0.87 [0.56-1.34]death33/24838/248Horby (RCT)4%0.96 [0.89-1.04]death1,222/7,3511,299/7,541Abdelwahab-8%1.08 [0.15-3.82]ventilation11/316/36Al Harthi (PSM)27%0.73 [0.56-0.97]death98/176107/173Kim (PSM)34%0.66 [0.36-1.23]death14/12423/135Tau​2 = 0.03; I​2 = 71.4%Late treatment25%0.75 [0.63-0.89]1,406/8,9021,557/9,49725% improvementYuan4%0.96 [0.47-1.72]death11/5229/131Improvement, RR [CI]TreatmentControlOsborne (PSM)59%0.41 [0.35-0.48]death272/6,300661/6,300Mulhem-14%1.14 [0.93-1.40]death300/1,354216/1,865Chow (PSM)19%0.81 [0.76-0.87]death1,280/6,7812,271/10,566Kim (PSM)-700%8.00 [1.07-59.6]death6/151/20Tau​2 = 0.19; I​2 = 96.5%PrEP17%0.83 [0.54-1.30]1,869/14,5023,178/18,88217% improvementAll studies25%0.75 [0.62-0.90]3,275/23,4044,735/28,37925% improvement14 aspirin COVID-19 studiesc19aspirin.com Sep 24, 2021Tau​2 = 0.08; I​2 = 91.6%; Z = 3.14Effect extraction pre-specifiedFavors aspirinFavors control
Database of all aspirin COVID-19 studies. Submit updates/corrections.
Sep 4
PrEP Kim et al., Medicina, doi:10.3390/medicina57090931 (Peer Reviewed) death, ↑700.0%, p=0.03 Aspirin Is Related to Worse Clinical Outcomes of COVID-19
Details   Retrospective database analysis of 22,660 patients tested for COVID-19 in South Korea. There was no significant difference in cases according to aspirin use. Aspirin use before COVID-19 was related to an increased death rate and aspirin u..
Sep 3
Late Al Harthi et al., Research Square, doi:10.21203/rs.3.rs-872891/v1 (Preprint) death, ↓27.0%, p=0.03 Evaluation of low-dose aspirin use among COVID-19 critically ill patients: A Multicenter Propensity Score Matched Study
Details   Retrospective 1,033 critical condition patients, showing lower in-hospital mortality with aspirin in PSM analysis. Patients receiving aspirin also had a higher risk of significant bleeding, although not reaching statistical significance. ..
Aug 29
PrEP Chow et al., Journal of Thrombosis and Haemostasis, doi:10.1111/jth.15517 (Peer Reviewed) death, ↓19.0%, p<0.005 Association of Pre-Hospital Antiplatelet Therapy with Survival in Patients Hospitalized with COVID-19: A Propensity Score-Matched Analysis
Details   PSM retrospective 6,781 hospitalized patients ≥50 years old in the USA who were on pre-hospital antiplatelet therapy (84% aspirin), and 10,566 matched controls, showing lower mortality with treatment.
Jul 30
Late Abdelwahab et al., Clinical Drug Investigation, doi:10.1007/s40261-021-01061-2 (Peer Reviewed) ventilation, ↑7.8%, p=0.93 Acetylsalicylic Acid Compared with Enoxaparin for the Prevention of Thrombosis and Mechanical Ventilation in COVID-19 Patients: A Retrospective Cohort Study
Details   Retrospective 225 hospitalized patients in Egypt, showing significantly lower thromboembolic events with aspirin treatment, but no significant difference in the need for mechanical ventilation.
Jun 8
Late Horby et al., medRxiv, doi:10.1101/2021.06.08.21258132 (Preprint) death, ↓4.0%, p=0.35 Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Details   RCT 14,892 very late stage (9 days from symptom onset) hospitalized patients, not showing a significant difference in mortality with treatment. A statistically significant increased chance of hospital discharge was found for treatment <= ..
May 19
Late Sahai et al., Vascular Medicine, doi:10.1177/1358863X211012754 (Peer Reviewed) death, ↓13.2%, p=0.53 Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19
Details   PSM retrospective 1,994 PCR+ patients in the USA, not showing a significant difference in mortality with aspirin treatment.
Apr 7
PrEP Mulhem et al., BMJ Open, doi:10.1136/bmjopen-2020-042042 (Peer Reviewed) death, ↑13.9%, p=0.21 3219 hospitalised patients with COVID-19 in Southeast Michigan: a retrospective case cohort study
Details   Retrospective database analysis of 3,219 hospitalized patients in the USA. Very different results in the time period analysis (Table S2), and results significantly different to other studies for the same medications (e.g., heparin OR 3.06..
Apr 1
Late Chow et al., Anesthesia & Analgesia, doi:10.1213/ANE.0000000000005292 (Peer Reviewed) death, ↓47.0%, p=0.02 Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019
Details   Retrospective 412 hospitalized patients, 98 treated with aspirin, showing lower mortality, ventilation, and ICU admission with treatment.
Mar 31
Late Mura et al., Research Square, doi:10.21203/rs.3.rs-369927/v1 (Preprint) death, ↓20.3%, p=0.001 Real-world Evidence for Improved Outcomes with Histamine Antagonists and Aspirin in 22,560 COVID-19 Patients
Details   PSM retrospective TriNetX database analysis of 1,379 severe COVID-19 patients requiring respiratory support, showing lower mortality with aspirin (not reaching statistical significance) and famotidine, and improved results from the combin..
Feb 12
Late Liu et al., Medicine, doi:10.1097/MD.0000000000024544 (Peer Reviewed) death, ↓75.0%, p=0.03 Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19
Details   Retrospective PSM analysis of 232 hospitalized patients, 28 treated with aspirin, showing lower mortality with treatment. There was no significant difference in viral clearance.
Feb 11
PrEP Osborne et al., PloS ONE, doi:10.1371/journal.pone.0246825 (Peer Reviewed) death, ↓59.4%, p<0.0001 Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration
Details   Retrospective PSM analysis of pre-existing aspirin use in the USA, showing lower mortality with treatment.
Jan 21
Late Meizlish et al., American Journal of Hematology, doi:10.1002/ajh.26102 (Peer Reviewed) death, ↓47.8%, p=0.004 Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis
Details   Retrospective 638 matched hospitalized patients in the USA, 319 treated with aspirin, showing lower mortality with treatment.
Dec 18
2020
PrEP Yuan et al., Journal of Cellular and Molecular Medicine, doi:10.1111/jcmm.16198 (Peer Reviewed) death, ↓4.4%, p=0.89 Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease
Details   Retrospective 183 hospitalized patients in China, 52 taking low-dose aspirin prior to hospitalization, showing no significant difference with treatment.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit